The present studies investigated the expression of the two
Introduction
Astrocytomas are aggressive brain tumors that numerically exceed all other primary intracerebral neoplasms (1) . The malignant progression of astrocytomas is associated with de-differentiation and the morphology of the most malignant form, glioblastoma multiforme, has been likened to their embryonic progenitor cells (2) (3) (4) (5) .
The molecular events associated with the pathogenesis and maintenance of astrocytomas are unknown. Data linking the amplification and over-expression of certain protooncogenes encoding growth factors or their receptors with specific human tumors and patient survival time have been reported. For example, amplification of N-myc in human neuroblastomas has been correlated with the pathologic stage of the tumor (6) , and amplification of c-myc in advanced human lung cancer appears to be associated with shorter survival time (7) . Recently, it has been claimed that amplification of the HER-2/neu gene correlates with a shorter time to relapse and lower survival rate in women with breast and ovarian cancers (8) . Furthermore, amplification of HER-2/neu may identify a specific pathological subset of breast carcinomas (9) . Amplification and enhanced expression of the epidermal growth factor receptor (EGF-R) gene in certain primary human brain tumors of glial origin has been suggested to represent a particular feature of these tumors (10) . The presence of an amplified, highly expressed gene, called GLI, has been observed in a single human malignant glioma (1 1, 12 ).
An important finding is that cultured astrocytoma cells express the c-sis protooncogene (13, 14) . This gene is homologous to the transforming gene of the simian sarcoma virus (SSV),' which encodes the PDGF-2 chain of platelet-derived growth factor (15) (16) (17) (18) . PDGF (20) (21) (22) (23) . Astrocytoma cells in culture also express the gene encoding the PDGF-1 (A) chain of PDGF in addition to the c-sis PDGF-2 oncogene (14, 22) . Recent studies have demonstrated the expression of the two PDGF genes and the PDGF receptor (PDGF-R) gene in three primary human astrocytomas (24) . Normal astrocytes in culture express cell-surface PDGF receptors and are targets for the potent mitogenic action of PDGF (25) . However, these normal astrocytes do not express the PDGF genes. Therefore, the inappropriate expression of genes encoding PDGF and the coexpression of PDGF-R by astrocytes may represent important steps in the development, proliferation and maintenance of the malignant astrocyte. This possibility is strengthened by the finding that the intracranial injection of SSV, carrying the v-sis oncogene which encodes the PDGF-2 chain, can induce a high frequency of gliomas in newborn marmosets (26) .
The mitogenic action of PDGF is mediated through binding to specific cell surface PDGF-receptors. The receptor that binds human PDGF and the c-sis/PDGF-2 homodimer has been cloned from mouse and human fibroblasts (27, 28) , and is currently referred to as the b receptor (29, 30) . This receptor does not recognize the PDGF-1 homodimer which binds to a separate a receptor (29, 30) . This a receptor has been cloned recently from human cells and was shown to bind to all three PDGF isoforms (31). The PDGF-R cited in these studies refers to the b receptor that has a specificity for the c-sis/PDGF-2 homodimer and the human PDGF heterodimer.
In this study we present data on the co-expression of the two PDGF genes and the PDGF The cDNA probes for the present studies included c-sis/PDGF-2 (32); PDGF-I (A) (22) ; the sis/PDGF-2-specific PDGF-R (27); fl-actin (33); and glial fibrillary acidic protein (GFAP) (34) .
In situ hybridization (ISH). Fresh tumor tissue was fixed immediately after excision in ice-cold 4% paraformaldehyde for 2 h and then was allowed to sink in 30% sucrose PBS overnight at 4°C to decrease freezing artifacts. In situ hybridization utilizing "S-labeled, cRNA probes for c-sis and PDGF-receptor was performed on 8-,Om frozen sections according to the method of Hofler et al. (35) . In some sections in situ hybridization was followed by immunohistochemistry for GFAP (Dako Corp., Copenhagen, Denmark).
The specificity ofthe probes for in situ hybridization was controlled by Northern blot analysis and by hybridization of serial sections with noncomplementary RNA probes.
Immunocytochemistry. Tissues were prepared as described for ISH.
The tissue sections were hydrated in PBS, bleached with 0.3% H202 in methanol, and reacted with the appropriate antibody using the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA). The tissues were then counterstained with hematoxylin, dehydrated, cleared, and mounted. The specificity of the immunostaining was tested by replacing the primary antibody with preimmune sera, which should lead to negative results. The following specific antisera were used in these studies: polyclonal antisera against recombinant c-sis/PDGF-2 homodimer specific for the human PDGF heterodimer and PDGF-2 homodimer but not the PDGF-1 homodimer (Institute of Molecular Biology, Boston); PDGF- Figs. 1-3 . The degree of expression varied among the samples tested, and it was significantly weaker than the c-sis gene expression. This necessitated a longer exposure time (10 d) during autoradiography causing significant background expression of 18S and 28S RNA. In contrast, the exposure time for c-sis was only 24 h. The PDGF-I gene expression appears to be independent of the expression of the c-sis protooncogene.
Expression of the PDGF-R gene. The PDGF-R gene was expressed by all astrocytomas tested. The intensity of the expression differed significantly among the individual astrocytoma tissues examined. An important finding was the identification of novel PDGF-R transcripts of -3.2 and 7.2 kb, compared to the expected 5.3 kb transcript. These novel transcripts were not present in RNA derived from the control U1240MG cell lines (Fig. 3 ) or in RNA derived from primary human meningiomas (36a). Studies in progress indicate that the 3.2-kb receptor transcript which is predominant in lane 21 ( Fig. 2) retains the receptor kinase region as judged by immunostaining ofthe tissue with antisera raised against the synthetic peptide to the kinase region of the receptor.
Localization of PDGF and PDGF-R mRNA's in astrocytoma and in nonmalignant brain tissues. Northern blot analysis demonstrated the co-expression ofthe PDGF and PDGF-R genes by primary human astrocytoma tissue. Localization of the cells expressing these genes in the primary tissue was examined by in situ hybridization. As shown in Fig. 4 , ISH demonstrated the expression of c-sis/PDGF-2 mRNA in tumor cells and in capillary endothelial cells as identified by light microscopy. For further cell identification, ISH in astrocytoma tissue was combined with immunostaining using antibody to GFAP. As shown in Fig. 5 , c-sis mRNA (Fig. 5 A) and PDGF-R mRNA (Fig. 5 B) were strongly expressed in tumor cells, including dividing cells that were stained weakly by GFAP. This is consistent with previous findings indicating that the more primitive and anaplastic cells in astrocytomas express GFAP weakly, or not at all (37, 38) .
ISH in five nonmalignant brain tissues demonstrated a strong expression ofPDGF-R mRNA but not ofc-sis/PDGF-2 mRNA. Fig. 6 presents an example of the expression of PDGF-R mRNA (Fig. 6, A-B) in the astrocytes of nonmalignant brain tissue, and the absence of c-sis mRNA expression in the same tissue (Fig. 6, C-D) . In this study we combined ISH with immunostaining with GFAP antibody in order to facilitate the recognition of the cell types expressing the mRNA. However, this combined process of ISH and immunostaining tends to decrease the sensitivity of mRNA detection. This becomes evident from the ISH data shown in Fig. 7 which demonstrate the strong expression of PDGF-R mRNA in the nonmalignant brain tissue (Fig. 7, A-B ) and the absence of c-sis mRNA expression in the same tissue (Fig. 7, C-D) . The data shown in Fig. 7 did not include the combined step of immunostaining with GFAP, allowing for a more efficient detection of mRNA. The specificity of the ISH data was controlled with ISH of serial sections using noncomplementary "sense" RNA probes. These control data with the sense probes did not demonstrate significant mRNA expression. These (Fig. 3) .
ISH failed to localize the PDGF-I mRNA in astrocytoma tissue due to a weak expression of this gene. This is consistent with the Northern blot analysis data, which indicated a weak expression of the PDGF-1 gene in astrocytoma tissue.
Expression of PDGF-like and PDGF-R-like proteins. Immunocytochemistry of astrocytoma tissue demonstrated the expression of both PDGF-like and PDGF-R-like proteins, using specific anti-PDGF-2 homodimer, and anti-receptor antisera (Fig. 8, A and C) . The specificity of these findings was checked by preincubating the antisera with excess recombinant PDGF-2 homodimer (50 ng) or the synthetic receptor peptide (100 ng), which provided negative results (Fig. 8, B and D). Control, nonmalignant brain tissue expressed only PDGF-R-like but not PDGF-like proteins (data not shown).
Discussion
The present findings have demonstrated the coexpression of the two PDGF genes together with the PDGF-R gene by a large number of primary human astrocytomas. All of the 29 primary tumors included in our data expressed both the c-sis/ PDGF-2 protooncogene and the PDGF-R gene, and 27 of the tumors also expressed the PDGF-1 gene. In situ hybridization demonstrated a strong expression of c-sis mRNA in tumor cells. Capillary endothelial cells in astrocytomas also expressed c-sis mRNA. This is not surprising since neovascularization is associated with astrocytomas and expression of the c-sis protooncogene by endothelial cells has been reported previously (39, 40) . A strong expression of PDGF-R mRNA was also shown in the tumor cells. The chemistry. These findings suggest the presence of an autocrine mechanism that involves the coexpression of a potent mitogenic growth factor and its receptor. This coexpression may contribute to the unregulated growth of the malignant astrocytes. A link between sis/PDGF-2 expression and transformation has been suggested to explain the ability of the SSV to induce transformation in cell culture (16, 17, 41) , and gliomas in monkeys (26) . Neoplastic transformation induced by the v-sis oncogene was attributed to the constitutive expression of a PDGF-like mitogen by the transformed cells causing sustained, unregulated cell proliferation (41) . Nonmalignant brain tissue expressed only the PDGF-R and PDGF-I genes, but not the c-sis/PDGF-2 protooncogene. Northern blot analysis of a single specimen and in situ hybridization of five specimens failed to recognize expression ofc-sis mRNA in normal cerebral cortex. Similarly, antisera against the PDGF-2 homodimer also failed to detect the presence of PDGF-like proteins in brain tissue. These data may indicate that the c-sis mRNA is inappropriately expressed in astrocytoma tissue. This is consistent with in vitro findings that demonstrated the inappropriate expression of c-sis mRNA in established cell lines derived from human tumors such as glioblastoma, fibrosarcoma, and osteosarcoma (13, 14, 42 
